This is a summary of some of the points raised in a round table discussion on occupational health and in two workshops on staff monitoring, held as part of ISOPP IV. It is not intended as a comprehensive review on these issues. It is, however, intended to focus discussion on some of the controversial areas from the perspective of a genetic toxicologist. Pharmacists who have points to add or disagree with, or who wish to discuss or debate these issues further might address such comments as "Letters to the editor" in this journal.
Kaldor JM, Day NE, Hemminki K.Quantifying the carcinogenicity of antineoplastic drugs. Eur J Cancer Clin Oncol.1988;24:703-711.
2.
Hawkins MM, Kinnear Wilson LM, Stovall MA. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukemia after childhood cancer. Br Med J.1992;304:951-958.
3.
Ferguson LR, Baguley BCTopoisomerase II enzymes and mutagenicity. Environ Mol Mutagen.1994;24: 245-267.
4.
Sieber SM, Adamson RHToxicity of antineoplastic agents in man: Chromosomal aberrations, antifertility effects and carcinogenic potential. Adv Cancer Res.1975;22:57-155.
5.
Schilsky RL, Lewis BJ, Sherins RJGonadal function in patients receiving chemotherapy for cancer. Ann Int Med.1980;93:109 -114.
6.
Buchanan JF, DavisLj. Drug induced infertility. Drug Intell Clin Pharm.1984;18:122-132.
7.
Gershenon DM . Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumours . J Clin Oncol.1988;6:270 -275.
8.
Falck K., Grohn P., Sorsa M.Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979;1: 1250-1251.
9.
Ferguson LRMutagenic properties of anticancer drugs. In: Ponder BAJ, Waring MJ, eds. The Genetics of Cancer. Lancaster: Kluwer Academic Publishers; 1995:177-215.
10.
Nikula E., Kivinitty K., Leisti J., Taskinen PJChromosomal aberrations in lymphocytes of nurses handling cytotoxic drugs . Scand J Work Environ Health. 1984;10:71-74.
11.
Pohlova H., Cerna M., Rossner P.Chromosomal abberations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res. 1986 ;174:213-217.
12.
Cooke J., Williams J., Morgan RJ, Calvert RTEnvironmental monitoring of personnel who handle cytotoxic drugs. Pharmaceutical J.1987;239(Suppl): 6452- 6453.
13.
Sorsa M., Pyy L., Salomaa S., Nylund L., Yager JWBiological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res. 1988 ;204:465-479.
14.
Ferguson LR , Everts R., McKinnon HM, Gerred AJMonitoring of drug absorption by pharmacists and oncology nurses in four New Zealand Hospitals using estimation of cytokinesis-blocked micronuclei. Australian JHosp Pharmacol.1990;20:212-221.
15.
Anderson D. , Sorsa M., Waters MDThe parallelogram approach in studies of genotoxic effects. Mutat Res.1994;313:101-115.
16.
de WerkNeal A., Wadden RA, Chiou WLExposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm.1983;40:597- 601.
17.
Nguyen TV, Theiss JC, Matney TSExposure of pharmacy personnel to mutagenic antincoplastic drugs. Cancer Res.1982;42:4792- 4796.
18.
Sessink PJ, Van-de-Kerkhof MC, Anzion RB, Noordhoek J., Bos RPEnvironmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route?Arch Environ Health. 1994;49:165-169.
19.
Sessink PJ, de-Roos JH, Pierik FH, Anzion RB, Bos RPOccupational exposure of animal caretakers to cyclophosphamide. J Occup Med.1993;35:47-52.
20.
Ensslin AS, Stoll Y., Pethran A., Pfaller A., Rommelt H., Fruhmann G.Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med.1994;51:229-233.
21.
Ferguson LR , Denny WAAnticancer drugs: An underestimated risk or an underutilised resource in mutagenesis. Mutat Res . 1995 (in press).
22.
Takeda S., Shimazoe T., Sato K., Sugimoto Y., Tsuruo T., Kono A.Differential expression of DNA topoisomerase-I gene between CPT-11 acquired-resistant and native-resistant human pancreatic tumor cell lines detected by RNA/PCR-based quantitation assay. Biochem Biophys Res Commun. 1992;184:618- 625.
23.
Kyrtopoulos SA , Souliotis VL, Valavanis C., Boussiotis VA, Pangalis GAAccumulation of 06-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects. Environ Health Perspect. 1993;99:143-147.
24.
Fenech M., Morley AACytokinesis-block method in human lymphocytes: Effect of in vivo aging and low-dose x-irradiation. Mutat Res. 1986 ;161:193-198.
25.
Fenech M., Morley AA, Denham J.The cytokinesis-block micronucleus assay: A sensitive technique for measuring radiation-induced chromosome damage. Proceedings of the International Conference "Health effects of low-dose ionising radiation— Recent advances and their implications." Organised by the British Nuclear Society and co-sponsored by the European Nuclear Society in London, 11-14 May 1987 1988:29-33.
26.
Ferguson LR , Everts R., Robbie MA, et al. The use within New Zealand of cytogenetic approaches to monitoring of hospital pharmacists for exposure to cytotoxic drugs: report of a pilot study in auckland. Australian J Hosp Pharmacol.1988;18:228-233.
27.
New Zealand Hospital Pharmacists' Association. Oncology Pharmacy Practice Manual. v. 1, 1991 (Handford M, ed. Cytotoxic Drugs).
28.
Hagmar L., Brogger A., Hansteen IL, et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res.1994;54:2919-2922.
